Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Jeffrey Alan Barnes, M.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Haydu JE, Maron JS, Redd RA, Gallagher KME, Fischinger S, Barnes JA, Hochberg EP, Johnson PC, Takvorian RW, Katsis K, Portman D, Ruiters J, Sechio S, Devlin M, Regan C, Blumenthal KG, Banerji A, Judd AD, Scorsune KJ, McGree BM, Sherburne MM, Lynch JM, Weitzman JI, Lei M, Kotton CN, Dighe AS, Maus MV, Alter G, Abramson JS, Soumerai JD. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Adv. 2022 03 22; 6(6):1671-1683. PMID: 35073571; PMCID: PMC8789382.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  2. Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, Matasar MJ, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021 Dec; 8(12):e879-e890. PMID: 34826411; PMCID: PMC9326222.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  3. Abramson JS, Irwin KE, Frigault MJ, Dietrich J, McGree B, Jordan JT, Yee AJ, Chen YB, Raje NS, Barnes JA, Davis B. Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer. 2019 Nov 01; 125(21):3692-3698. PMID: 31503324.
    Citations: 13     Fields:    Translation:Humans
  4. Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019 08 15; 134(7):606-613. PMID: 31186274.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  5. Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 05 16; 133(20):2212-2221. PMID: 30808634.
    Citations: 67     Fields:    Translation:Humans
  6. Barnes JA, Redd R, Fisher DC, Hochberg EP, Takvorian T, Neuberg D, Jacobsen E, Abramson JS. Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study. Hematol Oncol. 2018 Oct; 36(4):633-637. PMID: 29956350.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  7. Lorenzo ME, Carter JB, Barnes JA, Nazarian RM. CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 19-2016. A 65-Year-Old Man with End-Stage Renal Disease and a Pruritic Rash. N Engl J Med. 2016 Jun 23; 374(25):2478-88. PMID: 27332907.
    Citations: 1     Fields:    Translation:HumansCells
  8. Lowry KP, Turan EA, Eisenberg J, Kong CY, Barnes JA, Pandharipande PV. Projected Effects of Radiation-Induced Cancers on Life Expectancy in Patients Undergoing CT Surveillance for Limited-Stage Hodgkin Lymphoma: A Markov Model. AJR Am J Roentgenol. 2015 Jun; 204(6):1228-33. PMID: 26001232.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  9. Barnes JA, Abramson JS. Case 35-2013: A man with confusion and malaise. N Engl J Med. 2014 02 20; 370(8):784. PMID: 24552343.
    Citations:    Fields:    Translation:Humans
  10. Barnes JA, Abramson JS, Scott JA, Sohani AR. Case of the Massachusetts General Hospital: Case 35-2013: a 77-year-old man with confusion and malaise. N Engl J Med. 2013 Nov 14; 369(20):1946-57. PMID: 24224628.
    Citations: 1     Fields:    Translation:Humans
  11. Barnes JA, Abramson JS. R-CHOP: does one size fit all in diffuse large B cell lymphoma? Acta Haematol. 2014; 131(3):153-5. PMID: 24192325.
    Citations:    Fields:    Translation:Humans
  12. Carter JB, Barnes JA, Niell BL, Nardi V. Case records of the Massachusetts General Hospital. Case 24-2013. A 53-year-old woman with erythroderma, pruritus, and lymphadenopathy. N Engl J Med. 2013 Aug 08; 369(6):559-69. PMID: 23924007.
    Citations:    Fields:    Translation:Humans
  13. Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA, Takvorian RW, Neuberg D, Hochberg EP, Abramson JS. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014 Mar; 55(3):538-43. PMID: 23734654.
    Citations: 31     Fields:    Translation:Humans
  14. Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberg DS, Hochberg EP. Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma. 2013 Sep; 54(9):1915-20. PMID: 23289359.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  15. Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, Armand P, Joyce R, Sohani AR, Rodig SJ, Neuberg D, Fisher DC, Abramson JS. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013 Apr; 98(4):615-9. PMID: 23144193.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  16. Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010 Sep 15; 116(18):4283-90. PMID: 20564149.
    Citations: 67     Fields:    Translation:Humans
  17. Barnes JA, Abramson JS. Adult T-cell leukemia/lymphoma: complexities in diagnosis and novel treatment strategies. Oncology (Williston Park). 2009 Dec; 23(14):1267, 1270. PMID: 20120839.
    Citations:    Fields:    Translation:Humans
  18. Tischkau SA, Mitchell JW, Pace LA, Barnes JW, Barnes JA, Gillette MU. Protein kinase G type II is required for night-to-day progression of the mammalian circadian clock. Neuron. 2004 Aug 19; 43(4):539-49. PMID: 15312652.
    Citations: 22     Fields:    Translation:AnimalsCells
  19. Barnes JW, Tischkau SA, Barnes JA, Mitchell JW, Burgoon PW, Hickok JR, Gillette MU. Requirement of mammalian Timeless for circadian rhythmicity. Science. 2003 Oct 17; 302(5644):439-42. PMID: 14564007.
    Citations: 69     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Barnes's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (147)
Explore
_
Co-Authors (37)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.